Trials / Withdrawn
WithdrawnNCT03704077
An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
A Randomized, Active-Controlled, Open-Label, Phase 2 Clinical Trial of BMS-986213, in Combination With Various Standard-of-Care Therapeutic Regimens, in Participants With Recurrent, Locally Advanced, or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effectiveness of relatlimab plus nivolumab, alone or in combination with various standard-of-care treatments in participants with gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma that has come back or spread to other places in the body after prior therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Relatlimab + Nivolumab | Specified dose on specified days |
| BIOLOGICAL | Nivolumab | Specified dose on specified days |
| DRUG | Paclitaxel | Specified dose on specified days |
| DRUG | Ramucirumab | Specified dose on specified days |
Timeline
- Start date
- 2019-10-31
- Primary completion
- 2022-02-27
- Completion
- 2024-09-30
- First posted
- 2018-10-12
- Last updated
- 2020-05-19
Locations
84 sites across 14 countries: United States, Argentina, Australia, Brazil, Canada, Chile, Colombia, Germany, Italy, Mexico, Portugal, Puerto Rico, Romania, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03704077. Inclusion in this directory is not an endorsement.